Alma Mater Studiorum Università di Bologna Archivio istituzionale della ricerca

Six cases of chloracne in Italy: the success of combined therapy

This is the final peer-reviewed author's accepted manuscript (postprint) of the following publication:

Published Version:

Six cases of chloracne in Italy: the success of combined therapy / Chessa M.A.; La Placa M.; Patrizi A.; Virdi A.; Misciali C.; Fedrizzi G.; Filippi F.; Saurat J.-H.; Tengattini V.; Caletti M.T.; Mazzotti A.; Sorg O.; Fontao F.; Kaya G.; Neri I.. - In: JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY. - ISSN 0926-9959. - ELETTRONICO. - 35:2(2021), pp. e108-e111. [10.1111/jdv.16835]

Availability:

This version is available at: https://hdl.handle.net/11585/797691 since: 2021-03-16

Published:

DOI: http://doi.org/10.1111/jdv.16835

Terms of use:

Some rights reserved. The terms and conditions for the reuse of this version of the manuscript are specified in the publishing policy. For all terms of use and more information see the publisher's website.

This item was downloaded from IRIS Università di Bologna (https://cris.unibo.it/). When citing, please refer to the published version.

(Article begins on next page)



DR. MARCO ADRIANO CHESSA (Orcid ID: 0000-0002-0149-8870)

DR. MICHELANGELO LA PLACA (Orcid ID: 0000-0002-6894-3350)

PROF. ANNALISA PATRIZI (Orcid ID: 0000-0002-8398-0483)

DR. ANNALUCIA VIRDI (Orcid ID: 0000-0003-2323-8778)

DR. FEDERICA FILIPPI (Orcid ID: 0000-0001-8173-4257)

DR. VERA TENGATTINI (Orcid ID: 0000-0003-0700-0268)

DR. OLIVIER SORG (Orcid ID: 0000-0002-4172-4270)

Article type : Letter to Editor

Six cases of chloracne in Italy: the success of combined therapy

Marco Adriano Chessa¹ MD, Michelangelo La Placa^{1*} MD, Annalisa Patrizi¹ Prof, AnnaluciaVirdi¹, Misciali Cosimo¹ MD, Fedrizzi Giorgio² MD, Federica Filippi¹ MD, Jean-Hilaire Saurat³ Prof;, MD, Vera Tengattini¹ MD, Maria Turchese Caletti⁴ MD, Arianna Mazzotti⁴ MD, Olivier Sorg³ PhD, Fabienne Fontao³ PhD, Guerkan Kaya⁵ MD, Iria Neri¹ MD.

Affiliations:

¹Dermatology Unit, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy

²Istituto Zooprofilattico Sperimentale Lombardia Emilia Romagna-Chemical Department Bologna Italy

³Swiss Centre for Applied Human Toxicology, Dermatotoxicology Unit, University of Geneva, 1211 Geneva 4, Switzerland

⁴Diabetes Unit, Ravenna Internal Medicine Department, Romagna Local Health Unit, Ravenna, Italy.

This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the <u>Version of Record</u>. Please cite this article as <u>doi:</u> 10.1111/JDV.16835

This article is protected by copyright. All rights reserved

⁵University Hospital of Geneva, Switzerland

Running head: Chloracne and management

*Corresponding author

Dr. Michelangelo La Placa

Dermatology, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Via Massarenti, 1 – 40138 Bologna, Italy Ph: +39051-2144849; Fax +39-0512144867;

Email: michelangelo.laplaca@unibo.it

Manuscript text words: 637

Number of references: 10

Figures: 1 Tables: 1

Funding sources: None

Conflict of interest: None declared

Key Words: chloracne; acneic eruption; MADISH; aryl hydrocarbon receptor; expression of CYP1A1

Acknowledgment section: The patients in this manuscript have given written informed consent to publication of their case details.

Dear Editor,

Chloracne is a rare disfiguring disease related to dioxin exposure. A paucity of literature exists on the clinical manifestations of this disease and how best to treat it¹.

Dioxin acts in humans through an intracellular receptor, the aryl hydrocarbon receptor (AhR), which causes gene encoding of the enzyme cytochrome P450 1A1(CYP1A1). The expression of CYP1A1 in human skin is a diagnostic biomarker in acne-like lesions known as chloracne or "metabolizing acquired dioxin-induced skin hamartomas' (MADISH)^{2,3}.

In April 2014 six Pakistani patients (3 males and 3 females) with suspected chloracne were enrolled in this study at Dermatology Unit in Bologna (Italy) (Table 1).

The eruption had occurred suddenly and simultaneously (1 week before the consultation) in all the family members. Clinical examination revealed numerous small comedone-like lesions (open comedones and skin pits), and some inflammatory lesions such as cysts and folliculitis. In addition, the skin appeared rough and wizened, with a grayish pigmentation (Figure 1a-d).

Histological examination was consistent with chloracne (Figure 1 e). CYP1A1 immunohistochemical analysis proved strongly positive in patients No 1 and 2 (Figure 1f).

The chloracne/MADISH score proposed by Fabbrocini et al. was used to assess the diagnosis² which is likely when the score is $\ge 6^2$.

In our sample the chloracne/MADISH score, laboratory analyses and abdominal ultrasound were assessed (Table 1).

Toxicological exams were performed in all patients in serum of the six patients. High values of 2,3,4,6,7,8-(HxCDF), 1,2,3,4,6,7,8,9-(OCDD) and PCB 105, 118 and 157, were detected especially in two adult male patients (No 1 and 2). All foods recently assumed were analysed but resulted negative for dioxins. The culprit for the dioxin poisoning was not detected.

All patients included in the study were put on a diet with a reduced intake of saturated fatty acids and simple sugar, and an increase in the consumption of fruit, vegetables and whole foods. Regular fibre consumption was prescribed, together with daily physical activity, aimed at weight loss, bowel transit and mobilisation, and excretion of dioxins from adipose tissue storage.

In the 3 adults a pharmacological therapy with a fenofibrate 145 mg once a day plus lipidium colonfit twice a day was also performed, combined with a mechanical dermabrasion and multiple micro punch extraction under local anaesthesia. The 3 children were treated with topical adapalene 0.1% gel or topical tretinoin 0.05% cream producing exfoliation until complete healing of the skin in two years.

The combined metabolic and dermatologic therapy lasted 16 months leading to a normalization of triglyceride and cholesterol blood levels, and complete resolution of acneiform lesions with the persistence of pit scars (Figure 1 g-i). Abdominal ultrasound also showed a marked improvement in steatosis. Over the following 3 years laboratory and ultrasound exams were monitored resulting normal.

The sudden onset of a large number of comedones on the face and neck in the same household should lead the clinician to consider chloracne⁵. Histopathological findings and the increased expression of CYP1A1 in the skin at immunohistochemistry are the key markers for differential diagnosis^{6,7}. Familial comedones syndrome was excluded².

In our sample more severe manifestations in patients 1 and 2 were probably related to the high serum level of PCB that promoted an overstimulation of AhR favouring the expression of its signalling pathway⁷.

The therapeutic approach for chloracne patients is still an open topic. However, interference with the absorption of dietary organochlorines (OCs) by nutritional intervention and administration of drugs such as fenofibrate and Lipidium colonfit is a possible strategy to reduce systemic accumulation of OCs and increases the faecal excretion of DDT and DDE⁸⁻¹⁰. Finally, mechanical dermabrasion is as a useful therapy in clearing chloracne cutaneous lesions³.

In conclusion, this Italian case series has shown that PCBs could promote an overstimulation of AhR in the skin, favouring the consequent acneic eruption. A combined dermatologic and metabolic therapy can lead to a complete healing of chloracne.

REFERENCES

- 1. Baccarelli A, Pesatori AC, Consonni D, et al. Health status and plasma dioxin levels in chloracne cases 20 years after the Seveso, Italy, accident. Br J Dermatol 2005;152:459–465.
- 2. Fabbrocini G, Kaya G, Caseiro Silverio P, et al. Aryl Hydrocarbon Receptor Activation in Acne Vulgaris Skin: A Case Series from the Region of Naples, Italy. Dermatology 2015;231:334-8.
- 3. Saurat JH, Kaya G, Saxer-Sekulic N, et al. The cutaneous lesions of dioxin exposure: lessons from the poisoning of Victor Yushchenko. Toxicol Sci 2012;125:310-7.
- 4. Menotta S, D'Antonio M, Diegoli G, Montella L, Raccanelli S Fedrizzi G. Depletion study of PCDD/Fs and dioxini like PCBs concentration in contaminated home-produced eggs. Preliminary study". Analitica Chimica Acta 2010;672:50-54
- 5. Rerknimitr P, Korkij W, Wititsuwannakul J, Panmontha W, Suphapeetiporn K, Shotelersuk V. Expanding phenotypic spectrum of familial comedones. Dermatology 2014;228:215-9.
- 6. Passarini B, Infusino SD, Kasapi E. Chloracne: still cause for concern. Dermatology 2010;221:63-70.
- 7. Baccarelli A, Pesatori AC, Masten SA, Patterson DG Jr, Needham LL, Mocarelli P, Caporaso NE, Consonni D, Grassman JA, Bertazzi PA, Landi MT: Aryl-hydrocarbon receptor-dependent pathway and toxic effects of TCDD in humans: a population based study in Seveso, Italy. Toxicol Lett 2004; 149: 287–293.

This article is protected by copyright. All rights reserved

- 8. Jandacek RJ, Heubi JE, Buckley DD, Khoury JC, Turner WE, Sjödin A, Olson JR, Shelton C, Helms K, Bailey TD, Carter S, Tso P, Pavuk M. Reduction of the body burden of PCBs and DDE by dietary intervention in a randomized trial. J Nutr Biochem. 2014 Apr;25(4):483-8.
- P. Arguin H, Sánchez M, Bray GA, Lovejoy JC, Peters JC, Jandacek RJ, Chaput JP, Tremblay A. Impact of adopting a vegan diet or an olestra supplementation on plasma organochlorine concentrations: results from two pilot studies. Br J Nutr. 2010 May;103(10):1433-41.
- 10. Cohn WJ, Boylan JJ, Blanke RV, Fariss MW, Howell JR, Guzelian PS. Treatment of chlordecone (Kepone) toxicity with cholestyramine. Results of a controlled clinical trial. N Engl J Med 1978;298: 243–8

Figure 1: **(a,b)** In patient No 1 numerous small open comedones and skin pits, and some inflammatory lesions such as cysts and folliculitis involved the face, especially the forehead, the temporal, periauricular and mandibular area in the adult patient. A grayish skin pigmentation was evident on the periorbital site. **(c,d)** In patients Nos 4 and 5 small open comedones areas on grayish skin background involved mainly the forehead, malar, mandibular areas and the neck. **(e)** The epidermis showed follicular hyperkeratosis with fairly marked hair follicle cystic infundibulum and disappearance of sebaceous glands, as well as moderate-dense mixed, granulomatous infiltrate around the follicular infundibulum, which was plugged by orthokeratotic cells. **(f)** CYP1A1 immunohistochemical analysis with the use of an immunoperoxidase technique showed a strong uniform homogeneous positivity (100 μm). **(g-i)** Patients No 1, 4, 5 after three years of follow-up. Complete healing of cysts and folliculitis of the face after combined dermatologic and metabolic therapy.

Table 1: Histological, CYP1A1 immunohistochemical, laboratory analyses and abdominal ultrasound in our case series. Chloracne/MADISH score was calculated for each patient.

| PATIENT No | AGE | SEX | LABORATORY | ABDOMEN | MADISH/CHLORACNE SCORE | |
|------------|-----|-----|-----------------------------|------------------|--|--------|
| | | | FINDINGS | ULTRASOUND | | |
| 1 (father) | 39 | М | triglycerides 2120 mg/dl | Steatosis | -Number of sebaceous glands: | 2 |
| | | | total cholesterol 419 mg/dl | | -Cystic lesions: | 2 |
| | | | γ-GT 69 U/L | | -Mantle-like epithelial projections: | 2 |
| | | | | | -CYP1A1 immunohistochemistry, Distribution: | 2 |
| | | | | | -CYP1A1 immunohistochemistry, Intensity: | 2 |
| | | | | | | |
| | | | | | TOTA | AL: 10 |
| | | | | | | |
| 2 | 38 | М | triglycerides 1005 mg/dl | Steatosis | Number of sebaceous glands: | 2 |
| (father's | | | total cholesterol 239 mg/dl | | -Cystic lesions: | 2 |
| brother) | | | | | -Mantle-like epithelial projections: | 2 |
| | | | | | -CYP1A1 immunohistochemistry, Distribution: | 2 |
| | | | | | -CYP1A1 immunohistochemistry, Intensity: | 2 |
| | | | | | _ | |
| | | | | | TOTA | AL: 10 |
| | | | | | | |
| 3 | 39 | F | triglycerides 822 mg/dl | Normal | Number of sebaceous glands: | 2 |
| (mother) | | | total cholesterol 310 mg/dl | | -Cystic lesions: | 2 |
| | | | | | -Mantle-like epithelial projections: | 2 |
| | | | | | -CYP1A1 immunohistochemistry, Distribution: | 0 |
| | | | | | -CYP1A1 immunohistochemistry, Intensity: | 0 |
| | | | | | тот. | AL: 6 |
| | | | | | | |
| 4 | 5 | М | triglycerides 213 mg/dl | Hepatomegaly | Number of sebaceous glands: | 2 |
| (son) | | | total cholesterol 221 mg/dl | longitudinal | -Cystic lesions: | 2 |
| (30.1.) | | | amylases 113 U/L | diameter > 12 cm | -Mantle-like epithelial projections: | 2 |
| | | | LDL 189 mg/dl | diameter > 12 cm | -CYP1A1 immunohistochemistry, Distribution: | 0 |
| | | | - | | -CYP1A1 immunohistochemistry, Intensity: | 0 |
| | | | | | | |
| | | | | | тот | AL: 6 |
| | | | | | | |
| 5 | 4 | М | triglycerides 190 mg/dl | Hepatomegaly | Number of sebaceous glands: | 2 |
| | | | total cholesterol 189 mg/dl | longitudinal | -Cystic lesions: | 2 |
| (son) | | | | | | |
| (şon) | | | | diameter > 8 cm | -Mantle-like epithelial projections: | 2 |
| (son) | | | | diameter > 8 cm | -Mantle-like epithelial projections: -CYP1A1 immunohistochemistry, Distribution: | 2 0 |

| D | | | | | тот | 'AL: 6 |
|------------|---|---|-----------------------------|--------|--|------------------|
| 6 | 7 | F | triglycerides 185 mg/dl | Normal | Number of sebaceous glands: | 2 |
| (daughter) | | | total cholesterol 201 mg/dl | | -Cystic lesions: -Mantle-like epithelial projections: -CYP1A1 immunohistochemistry, Distribution: -CYP1A1 immunohistochemistry, Intensity: | 2 2 0 0 |
| | | | | | тот | AL: 6 |

